10-K: Cadrenal Therapeutics Reports 2023 Annual Results, Focuses on Tecarfarin Development

Cadrenal Therapeutics' 2023 annual report highlights the company's focus on developing tecarfarin for rare cardiovascular conditions, while also detailing financial results and risks.

Summary

• Cadrenal Therapeutics is a clinical-stage biopharmaceutical company focused on developing tecarfarin, a novel anticoagulant.
• The company is targeting rare cardiovascular conditions where current anticoagulation therapies are inadequate.
• Tecarfarin has received orphan drug designation and fast-track designation from the FDA for specific indications.
• The company plans to initiate a pivotal Phase 3 clinical trial in 2025, subject to additional funding.
• Cadrenal reported a net loss of $8.36 million for 2023, which included $4.68 million of non-cash expenses.
• As of December 31, 2023, the company had cash and cash equivalents of approximately $8.4 million.
• The company estimates the annual U.S. market potential for tecarfarin to be in excess of $2 billion.
• Cadrenal has sub-licensed tecarfarin in China, Hong Kong, Macau, Taiwan and Thailand and is entitled to receive up to $52 million in milestone payments and royalties between 9% to 15% of net sales.
• The company relies on third-party manufacturers for the production of tecarfarin.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as the potential of tecarfarin and its regulatory designations, the company's financial situation and reliance on future funding create significant uncertainty. The document also highlights the risks associated with drug development and commercialization.

Positives

• Tecarfarin has shown a favorable safety profile in clinical trials with a low incidence of major bleeding.
• The drug targets a different metabolic pathway than warfarin, potentially leading to more reliable anticoagulation.
• The company has secured orphan drug and fast-track designations from the FDA, which could expedite the approval process.
• The company has identified a significant market opportunity for tecarfarin in rare cardiovascular conditions.
• The company has a sub-license agreement in place for tecarfarin in China, Hong Kong, Macau, Taiwan and Thailand which could provide future revenue.

Negatives

• The company has a limited operating history and a history of losses.
• The company's cash and proceeds from recent offerings will only fund operations for a limited time.
• The company will need to raise additional capital to fund its planned Phase 3 clinical trial.
• The company is dependent on the success of tecarfarin, which requires additional clinical testing.
• The company relies on third-party manufacturers for the production of tecarfarin.
• The company faces substantial competition from other pharmaceutical companies.
• The company's patents for tecarfarin expire in 2024 and 2025.

Risks

• The company has a limited operating history and a history of losses.
• The company's cash and proceeds from recent offerings will only fund operations for a limited time.
• The company will need to raise additional capital to fund its planned Phase 3 clinical trial.
• The company is dependent on the success of tecarfarin, which requires additional clinical testing.
• The company may not receive regulatory approval for tecarfarin, even if clinical trials are successful.
• The company faces substantial competition from other pharmaceutical companies.
• The company's patents for tecarfarin expire in 2024 and 2025.
• The company relies on third-party manufacturers for the production of tecarfarin.
• The company may experience delays in the enrollment of patients in clinical trials.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.
• The company's stock price has been extremely volatile.

Future Outlook

The company plans to initiate a pivotal Phase 3 clinical trial in 2025, subject to additional funding, and intends to explore the full potential of tecarfarin in additional indications, including the treatment of patients with LVADs and APS.

Management Comments

• The company's goal is to build a biopharmaceutical company with a foundation of product candidates that significantly advance patient care in rare cardiovascular conditions.
• The company intends to create a commercial infrastructure for its product candidates.

Industry Context

The document highlights the unmet need for effective anticoagulation therapies in rare cardiovascular conditions, where current treatments like warfarin and DOACs have limitations. This positions Cadrenal to potentially address a significant gap in the market.

Comparison to Industry Standards

• The document mentions that warfarin typically achieves a Time in Therapeutic Range (TTR) of 50-55%, while the target is 70%. In the EMBRACE-AC study, warfarin achieved a TTR of 71.5% due to the use of dose control centers, which is much higher than real-world practice.
• The document references the ARIES-HM3 study, which showed that warfarin achieved an average TTR of only 56% in LVAD patients, highlighting the need for better anticoagulation options.
• The document mentions that DOACs have not shown clinical benefits in certain patient populations, such as those with LVADs, ESKD and AFib, and thrombotic APS, or their efficacy and safety remains uncertain.
• The document mentions that the RENAL-AF trial, which was designed to evaluate anticoagulation therapy in hemodialysis patients with atrial fibrillation, was terminated early by its sponsor.
• The document mentions that the AXADIA study is currently recruiting patients to compare apixaban and vitamin-K antagonists in patients with atrial fibrillation and end-stage kidney disease.
• The document mentions that Merck received fast-track designation for its investigational anticoagulant therapy MK-2060 for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage kidney disease (ESKD).

Related Party Transactions

• The company entered into an agreement with Phamace, LLC, a consulting firm of which Quang Pham, the company's Chief Executive Officer, is the sole member, for advisory and administrative services.
• The company issued a convertible promissory note to John Murphy, a member of the company's board of directors.
• The company issued 450,000 shares of restricted common stock to Matthew Szot, its Chief Financial Officer.
• The company issued a convertible promissory note to Glynn Wilson, a member of the company's board of directors.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees may be affected by the company's financial performance and ability to secure funding.
• Patients with rare cardiovascular conditions could benefit from the development of tecarfarin.
• The company's suppliers and creditors may be impacted by its financial stability.

Next Steps

• The company intends to initiate a pivotal Phase 3 clinical trial in 2025, subject to additional funding.
• The company intends to explore the full potential of tecarfarin in additional indications, including the treatment of patients with LVADs and APS.
• The company intends to partner and/or in-license and/or acquire clinical-stage cardiovascular products to augment its current pipeline.
• The company intends to create a commercial infrastructure for its product candidates.

Key Dates

Keywords

tecarfarin, anticoagulant, cardiovascular, ESKD, AFib, LVAD, thrombosis, clinical trial, FDA, orphan drug, warfarin, DOAC, pharmaceutical, biopharmaceutical